Nah I know phase 2 will show potential to move to phase 3 NA-1 has the same results. Safety studies will also be positive as per NA-1. It’s the same drug class and multiple peptides have passed these points and all have failed in this drug class because these peptides couldn’t even show 1 percent efficacy. Having a long acting peptide in the same class won’t make a difference. It’s why the CEO in every recent interview states:
”We are looking at safety data, efficacy we just need to show any improvement” she’s hoping it’s not a NA-1 but the development of AGN all happened before these peptides all failed
- Forums
- ASX - By Stock
- AGN
- AGN Media thread
AGN Media thread, page-247
-
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AGN (ASX) to my watchlist
|
|||||
Last
79.0¢ |
Change
0.010(1.28%) |
Mkt cap ! $100.4M |
Open | High | Low | Value | Volume |
78.0¢ | 80.0¢ | 78.0¢ | $12.31K | 15.64K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2093 | 79.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
83.0¢ | 14798 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2093 | 0.790 |
1 | 65789 | 0.785 |
1 | 3439 | 0.780 |
2 | 30844 | 0.775 |
3 | 77341 | 0.770 |
Price($) | Vol. | No. |
---|---|---|
0.830 | 14798 | 3 |
0.835 | 10650 | 2 |
0.840 | 3571 | 1 |
0.850 | 620 | 1 |
0.870 | 13668 | 2 |
Last trade - 15.48pm 30/08/2024 (20 minute delay) ? |
Featured News
AGN (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online